Ignite Creation Date:
2024-05-06 @ 3:53 AM
Last Modification Date:
2024-10-26 @ 11:40 AM
Study NCT ID:
NCT02393859
Status:
COMPLETED
Last Update Posted:
2024-05-29
First Post:
2015-03-16
Brief Title:
Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk HR First Relapse B-precursor Acute Lymphoblastic Leukemia ALL
Sponsor:
Amgen
Organization:
Amgen
Organization Data
Organization:
Amgen
Class:
INDUSTRY
Study ID:
20120215
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Amgen
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None